A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorSkyline Therapeutics
About this trial
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Eligibility criteria
Qualifiers
nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;
Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to complete the study
Disqualifiers
Subjects who are judged by the investigator unsuitable for this study
Trial design
Treatments tested in this trial
- SKG0106
Treatment groups
83 Participants
are divided into 3 treatment groupsLocations
10China
The Second Hospital Of Anhui Medical University HefeiAnhui, China
Zhejiang Provincial People's Hospital HangzhouZhejiang, China
Eye Hospital, WMU (Zhejiang Eye Hospital) WenzhouZhejiang, China
Beijing Hospital Beijing China
Sponsors and collaborators
Skyline Therapeutics
Lead sponsor
Source ClinicalTrials.gov